The global market for Resistant Pseudomonas Aeruginosa Infections Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Resistant Pseudomonas Aeruginosa Infections Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Resistant Pseudomonas Aeruginosa Infections Drugs.

The Resistant Pseudomonas Aeruginosa Infections Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Resistant Pseudomonas Aeruginosa Infections Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Resistant Pseudomonas Aeruginosa Infections Drugs Market Report

Report Metric	Details
Report Name	Resistant Pseudomonas Aeruginosa Infections Drugs Market
CAGR	5%
Segment by Type	Semi-Synthetic Penicillin Cephalosporin Lactam Drugs Others
Segment by Application	Hospital Clinic Home Care
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	ContraFect Corp, Inhibrx LP, Achaogen Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Novartis AG, AmpliPhi Biosciences Corp, Biolytics Pharma, Shionogi & Co Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Resistant Pseudomonas Aeruginosa Infections Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Resistant Pseudomonas Aeruginosa Infections Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report?

Ans: The main players in the Resistant Pseudomonas Aeruginosa Infections Drugs Market are ContraFect Corp, Inhibrx LP, Achaogen Inc, LegoChem Biosciences Inc, Melinta Therapeutics Inc, Novartis AG, AmpliPhi Biosciences Corp, Biolytics Pharma, Shionogi & Co Ltd

What are the Application segmentation covered in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report?

Ans: The Applications covered in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report are Hospital, Clinic, Home Care

What are the Type segmentation covered in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report?

Ans: The Types covered in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report are Semi-Synthetic Penicillin, Cephalosporin, Lactam Drugs, Others

1 Resistant Pseudomonas Aeruginosa Infections Drugs Market Overview

1.1 Product Definition

1.2 Resistant Pseudomonas Aeruginosa Infections Drugs by Type

1.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Value Comparison by Type (2024 VS 2031)

1.2.2 Semi-Synthetic Penicillin

1.2.3 Cephalosporin

1.2.4 Lactam Drugs

1.2.5 Others

1.3 Resistant Pseudomonas Aeruginosa Infections Drugs by Application

1.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Home Care

1.4 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size Estimates and Forecasts

1.4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue 2020-2031

1.4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales 2020-2031

1.4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Competition by Manufacturers

2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers (2020-2025)

2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Resistant Pseudomonas Aeruginosa Infections Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Product Type & Application

2.7 Global Key Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Date of Enter into This Industry

2.8 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Competitive Situation and Trends

2.8.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Resistant Pseudomonas Aeruginosa Infections Drugs Players Market Share by Revenue

2.8.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Scenario by Region

3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2020-2031

3.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2020-2025

3.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region: 2026-2031

3.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2020-2031

3.3.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2020-2025

3.3.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2026-2031

3.4 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country

3.4.1 North America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2031)

3.4.3 North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country

3.5.1 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2031)

3.5.3 Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2020-2031)

3.6.3 Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country

3.7.1 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2031)

3.7.3 Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2031)

3.8.3 Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2020-2031)

4.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2020-2025)

4.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Type (2026-2031)

4.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2020-2031)

4.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2020-2031)

4.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2020-2025)

4.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Type (2026-2031)

4.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2020-2031)

4.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Type (2020-2031)

5 Segment by Application

5.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2020-2031)

5.1.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2020-2025)

5.1.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Application (2026-2031)

5.1.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2020-2031)

5.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2020-2031)

5.2.1 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2020-2025)

5.2.2 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Application (2026-2031)

5.2.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2020-2031)

5.3 Global Resistant Pseudomonas Aeruginosa Infections Drugs Price by Application (2020-2031)

6 Key Companies Profiled

6.1 ContraFect Corp

6.1.1 ContraFect Corp Company Information

6.1.2 ContraFect Corp Description and Business Overview

6.1.3 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.1.4 ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.1.5 ContraFect Corp Recent Developments/Updates

6.2 Inhibrx LP

6.2.1 Inhibrx LP Company Information

6.2.2 Inhibrx LP Description and Business Overview

6.2.3 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.2.5 Inhibrx LP Recent Developments/Updates

6.3 Achaogen Inc

6.3.1 Achaogen Inc Company Information

6.3.2 Achaogen Inc Description and Business Overview

6.3.3 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.3.5 Achaogen Inc Recent Developments/Updates

6.4 LegoChem Biosciences Inc

6.4.1 LegoChem Biosciences Inc Company Information

6.4.2 LegoChem Biosciences Inc Description and Business Overview

6.4.3 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.4.4 LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.4.5 LegoChem Biosciences Inc Recent Developments/Updates

6.5 Melinta Therapeutics Inc

6.5.1 Melinta Therapeutics Inc Company Information

6.5.2 Melinta Therapeutics Inc Description and Business Overview

6.5.3 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.5.5 Melinta Therapeutics Inc Recent Developments/Updates

6.6 Novartis AG

6.6.1 Novartis AG Company Information

6.6.2 Novartis AG Description and Business Overview

6.6.3 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.6.5 Novartis AG Recent Developments/Updates

6.7 AmpliPhi Biosciences Corp

6.7.1 AmpliPhi Biosciences Corp Company Information

6.7.2 AmpliPhi Biosciences Corp Description and Business Overview

6.7.3 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.7.4 AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.7.5 AmpliPhi Biosciences Corp Recent Developments/Updates

6.8 Biolytics Pharma

6.8.1 Biolytics Pharma Company Information

6.8.2 Biolytics Pharma Description and Business Overview

6.8.3 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.8.5 Biolytics Pharma Recent Developments/Updates

6.9 Shionogi & Co Ltd

6.9.1 Shionogi & Co Ltd Company Information

6.9.2 Shionogi & Co Ltd Description and Business Overview

6.9.3 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product Portfolio

6.9.5 Shionogi & Co Ltd Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Chain Analysis

7.2 Resistant Pseudomonas Aeruginosa Infections Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Resistant Pseudomonas Aeruginosa Infections Drugs Production Mode & Process Analysis

7.4 Resistant Pseudomonas Aeruginosa Infections Drugs Sales and Marketing

7.4.1 Resistant Pseudomonas Aeruginosa Infections Drugs Sales Channels

7.4.2 Resistant Pseudomonas Aeruginosa Infections Drugs Distributors

7.5 Resistant Pseudomonas Aeruginosa Infections Drugs Customer Analysis

8 Resistant Pseudomonas Aeruginosa Infections Drugs Market Dynamics

8.1 Resistant Pseudomonas Aeruginosa Infections Drugs Industry Trends

8.2 Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers

8.3 Resistant Pseudomonas Aeruginosa Infections Drugs Market Challenges

8.4 Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

ContraFect Corp

Inhibrx LP

Achaogen Inc

LegoChem Biosciences Inc

Melinta Therapeutics Inc

Novartis

AmpliPhi Biosciences Corp

Biolytics Pharma

Shionogi

List of Tables

Table 1. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Competitive Situation by Manufacturers in 2024

Table 4. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Resistant Pseudomonas Aeruginosa Infections Drugs Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Resistant Pseudomonas Aeruginosa Infections Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Resistant Pseudomonas Aeruginosa Infections Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Resistant Pseudomonas Aeruginosa Infections Drugs as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2020-2025)

Table 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2026-2031)

Table 21. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2020-2025)

Table 23. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2026-2031)

Table 25. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2020-2025)

Table 51. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Type (2026-2031)

Table 52. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2020-2025)

Table 53. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Type (2026-2031)

Table 54. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2020-2025)

Table 57. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Type (2026-2031)

Table 58. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Application (2020-2025)

Table 61. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs) by Application (2026-2031)

Table 62. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2020-2025)

Table 63. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Application (2026-2031)

Table 64. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2020-2025)

Table 67. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Application (2026-2031)

Table 68. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) by Application (2026-2031)

Table 70. ContraFect Corp Company Information

Table 71. ContraFect Corp Description and Business Overview

Table 72. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. ContraFect Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 74. ContraFect Corp Recent Developments/Updates

Table 75. Inhibrx LP Company Information

Table 76. Inhibrx LP Description and Business Overview

Table 77. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Inhibrx LP Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 79. Inhibrx LP Recent Developments/Updates

Table 80. Achaogen Inc Company Information

Table 81. Achaogen Inc Description and Business Overview

Table 82. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Achaogen Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 84. Achaogen Inc Recent Developments/Updates

Table 85. LegoChem Biosciences Inc Company Information

Table 86. LegoChem Biosciences Inc Description and Business Overview

Table 87. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. LegoChem Biosciences Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 89. LegoChem Biosciences Inc Recent Developments/Updates

Table 90. Melinta Therapeutics Inc Company Information

Table 91. Melinta Therapeutics Inc Description and Business Overview

Table 92. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Melinta Therapeutics Inc Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 94. Melinta Therapeutics Inc Recent Developments/Updates

Table 95. Novartis AG Company Information

Table 96. Novartis AG Description and Business Overview

Table 97. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. Novartis AG Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 99. Novartis AG Recent Developments/Updates

Table 100. AmpliPhi Biosciences Corp Company Information

Table 101. AmpliPhi Biosciences Corp Description and Business Overview

Table 102. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. AmpliPhi Biosciences Corp Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 104. AmpliPhi Biosciences Corp Recent Developments/Updates

Table 105. Biolytics Pharma Company Information

Table 106. Biolytics Pharma Description and Business Overview

Table 107. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. Biolytics Pharma Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 109. Biolytics Pharma Recent Developments/Updates

Table 110. Shionogi & Co Ltd Company Information

Table 111. Shionogi & Co Ltd Description and Business Overview

Table 112. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. Shionogi & Co Ltd Resistant Pseudomonas Aeruginosa Infections Drugs Product

Table 114. Shionogi & Co Ltd Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Resistant Pseudomonas Aeruginosa Infections Drugs Distributors List

Table 118. Resistant Pseudomonas Aeruginosa Infections Drugs Customers List

Table 119. Resistant Pseudomonas Aeruginosa Infections Drugs Market Trends

Table 120. Resistant Pseudomonas Aeruginosa Infections Drugs Market Drivers

Table 121. Resistant Pseudomonas Aeruginosa Infections Drugs Market Challenges

Table 122. Resistant Pseudomonas Aeruginosa Infections Drugs Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Resistant Pseudomonas Aeruginosa Infections Drugs

Figure 2. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Type: 2024 & 2031

Figure 4. Semi-Synthetic Penicillin Product Picture

Figure 5. Cephalosporin Product Picture

Figure 6. Lactam Drugs Product Picture

Figure 7. Others Product Picture

Figure 8. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Application: 2024 & 2031

Figure 10. Hospital

Figure 11. Clinic

Figure 12. Home Care

Figure 13. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size (2020-2031) & (US$ Million)

Figure 15. Global Resistant Pseudomonas Aeruginosa Infections Drugs Sales (2020-2031) & (K Pcs)

Figure 16. Global Resistant Pseudomonas Aeruginosa Infections Drugs Average Price (USD/Pcs) & (2020-2031)

Figure 17. Resistant Pseudomonas Aeruginosa Infections Drugs Report Years Considered

Figure 18. Resistant Pseudomonas Aeruginosa Infections Drugs Sales Share by Manufacturers in 2024

Figure 19. Global Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Share by Manufacturers in 2024

Figure 20. Global 5 and 10 Largest Resistant Pseudomonas Aeruginosa Infections Drugs Players: Market Share by Revenue in Resistant Pseudomonas Aeruginosa Infections Drugs in 2024

Figure 21. Resistant Pseudomonas Aeruginosa Infections Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 22. Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 23. North America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2020-2031)

Figure 24. North America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2020-2031)

Figure 25. U.S. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Canada Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2020-2031)

Figure 28. Europe Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2020-2031)

Figure 29. Germany Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. France Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. U.K. Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Italy Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Russia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Region (2020-2031)

Figure 35. Asia Pacific Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Region (2020-2031)

Figure 36. China Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Japan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. South Korea Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. India Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Australia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Taiwan Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Indonesia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Thailand Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Malaysia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Philippines Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2020-2031)

Figure 47. Latin America Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2020-2031)

Figure 48. Mexico Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Brazil Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Argentina Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Sales Market Share by Country (2020-2031)

Figure 52. Middle East and Africa Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Market Share by Country (2020-2031)

Figure 53. Turkey Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. Saudi Arabia Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. UAE Resistant Pseudomonas Aeruginosa Infections Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 56. Global Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Type (2020-2031)

Figure 57. Global Revenue Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Type (2020-2031)

Figure 58. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) by Type (2020-2031)

Figure 59. Global Sales Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Application (2020-2031)

Figure 60. Global Revenue Market Share of Resistant Pseudomonas Aeruginosa Infections Drugs by Application (2020-2031)

Figure 61. Global Resistant Pseudomonas Aeruginosa Infections Drugs Price (USD/Pcs) by Application (2020-2031)

Figure 62. Resistant Pseudomonas Aeruginosa Infections Drugs Value Chain

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-4U20267

Mon Nov 24 00:00:00 UTC 2025

Add to Cart

Global Anticoccidial Solutions Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-16R16865

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Bacterial Enteric Disease Testing Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-3F17301

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

Global Whooping Cough Vaccination Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-4B20221

Wed Nov 12 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Research Report 2025

Published Date: September 2025

Report Code: QYRE-Auto-13M3197

Global Resistant Pseudomonas Aeruginosa Infections Drugs Market Research Report 2025

FEATURED COMPANIES

Resistant Pseudomonas Aeruginosa Infections Drugs Market Size

Resistant Pseudomonas Aeruginosa Infections Drugs Market

Report Scope

Scope of Resistant Pseudomonas Aeruginosa Infections Drugs Market Report

Core Chapters

FAQ for this report

Who are the main players in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report?

What are the Application segmentation covered in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report?

What are the Type segmentation covered in the Resistant Pseudomonas Aeruginosa Infections Drugs Market report?

FEATURED COMPANIES

RELATED REPORTS